Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...

If the diagnosis of FH is certain, I advise you to continue taking Praluent, as it is likely to have a very large improvement in your chances of getting a heart attack.

Praluent and Repatha won U.S. approvals just weeks apart in 2015. Both drugs work to help lower “bad” LDL cholesterol by blocking the protein PCSK9.

Praluent® and Repatha® are both PCSK9 inhibitors (“PCSK9i) intended to help patients lower their low-density lipoprotein choleresterol. Regeneron alleges that Amgen is engaged in an ...

Praluent is supplied in 2 dosage strengths, 75mg/mL and 150mg/mL, in a single-dose prefilled pen. In children aged 8 to 11 years, Praluent should be given by a caregiver following proper training.

Q: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage ...

The Food and Drug Administration (FDA) has approved Praluent (alirocumab) as an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults with homozygous familial ...

Meeting Coverage > ACC Homozygous FH Falls to Praluent, Novel Agent — Drugs succeed in cutting LDL in extra-refractory form of high cholesterol by Ed Susman, Contributing Writer, MedPage Today ...

On October 29, 2020, the European Patent Office ruled in favor of Sanofi and Regeneron in their dispute concerning Amgen’s Praluent ® (alirocumab) patent. The EPO found invalid certain claims ...

George Yancopoulos, Regeneron Pharma’s top scientist, is still a bit bitter about the commercial flop of its cholesterol-lowering PCSK9 inhibitor Praluent.